PMID- 32033317
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1999-4923 (Print)
IS  - 1999-4923 (Electronic)
IS  - 1999-4923 (Linking)
VI  - 12
IP  - 2
DP  - 2020 Feb 5
TI  - Formulation of Folate-Modified Raltitrexed-Loaded Nanoparticles for Colorectal 
      Cancer Theranostics.
LID - 10.3390/pharmaceutics12020133 [doi]
LID - 133
AB  - Multifunctional nanoparticles (NPs) that enable the imaging of drug delivery and 
      facilitate cancer cell uptake are potentially powerful tools in tailoring 
      oncologic treatments. Here we report the development of a layer-by-layer (LbL) 
      formulation of folic acid (FA) and folate antimetabolites that have been 
      well-established for enhanced tumor uptake and as potent chemotherapeutics, 
      respectively. To investigate the uptake of LbL coated NPs, we deposited 
      raltitrexed (RTX) or combined RTX-FA on fluorescent polystyrene NPs. The 
      performance of these NP formulations was evaluated with CT26 murine colorectal 
      cancer (CRC) cells in vitro and in vivo to examine both uptake and cytotoxicity 
      against CRC. Fluorescence microscopy and flow cytometry indicated an increased 
      accumulation of the coated NP formulations versus bare NPs. Ex vivo near-infrared 
      (NIR) fluorescence imaging of major organs suggested the majority of NPs 
      accumulated in the liver, which is typical of a majority of NP formulations. 
      Imaging of the CRC tumors alone showed a higher average fluorescence from NPs 
      accumulated in animals treated with the coated NPs, with the majority of RTX 
      NP-treated animals showing the consistently-highest mean tumoral accumulation. 
      Overall, these results contribute to the development of LbL formulations in CRC 
      theranostic applications.
FAU - Rosch, Justin G
AU  - Rosch JG
AD  - Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State 
      University, Portland, OR 97201, USA.
FAU - DuRoss, Allison N
AU  - DuRoss AN
AD  - Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State 
      University, Portland, OR 97201, USA.
FAU - Landry, Madeleine R
AU  - Landry MR
AD  - Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State 
      University, Portland, OR 97201, USA.
FAU - Sun, Conroy
AU  - Sun C
AD  - Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State 
      University, Portland, OR 97201, USA.
AD  - Department of Radiation Medicine, School of Medicine, Oregon Health & Science 
      University, Portland, OR 97239, USA.
LA  - eng
GR  - R35 GM119839/GM/NIGMS NIH HHS/United States
GR  - 1R35GM119839-01/NH/NIH HHS/United States
PT  - Journal Article
DEP - 20200205
PL  - Switzerland
TA  - Pharmaceutics
JT  - Pharmaceutics
JID - 101534003
PMC - PMC7076500
OTO - NOTNLM
OT  - NIR imaging
OT  - folic acid
OT  - nanoparticles
OT  - raltitrexed
OT  - tangential flow filtration
COIS- The authors declare no conflict of interest.
EDAT- 2020/02/09 06:00
MHDA- 2020/02/09 06:01
PMCR- 2020/02/01
CRDT- 2020/02/09 06:00
PHST- 2020/01/01 00:00 [received]
PHST- 2020/01/28 00:00 [revised]
PHST- 2020/02/03 00:00 [accepted]
PHST- 2020/02/09 06:00 [entrez]
PHST- 2020/02/09 06:00 [pubmed]
PHST- 2020/02/09 06:01 [medline]
PHST- 2020/02/01 00:00 [pmc-release]
AID - pharmaceutics12020133 [pii]
AID - pharmaceutics-12-00133 [pii]
AID - 10.3390/pharmaceutics12020133 [doi]
PST - epublish
SO  - Pharmaceutics. 2020 Feb 5;12(2):133. doi: 10.3390/pharmaceutics12020133.